Fresenius Total Liab vs Common Stock Total Equity Analysis
FMS Stock | USD 21.25 0.73 3.56% |
Fresenius Medical financial indicator trend analysis is much more than just examining Fresenius Medical Care latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Fresenius Medical Care is a good investment. Please check the relationship between Fresenius Medical Total Liab and its Common Stock Total Equity accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
Total Liab vs Common Stock Total Equity
Total Liab vs Common Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Fresenius Medical Care Total Liab account and Common Stock Total Equity. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Fresenius Medical's Total Liab and Common Stock Total Equity is 0.54. Overlapping area represents the amount of variation of Total Liab that can explain the historical movement of Common Stock Total Equity in the same time period over historical financial statements of Fresenius Medical Care, assuming nothing else is changed. The correlation between historical values of Fresenius Medical's Total Liab and Common Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Liab of Fresenius Medical Care are associated (or correlated) with its Common Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock Total Equity has no effect on the direction of Total Liab i.e., Fresenius Medical's Total Liab and Common Stock Total Equity go up and down completely randomly.
Correlation Coefficient | 0.54 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Common Stock Total Equity
The total value of common stock equity held by shareholders, representing their ownership interest in the company.Most indicators from Fresenius Medical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Fresenius Medical Care current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At this time, Fresenius Medical's Tax Provision is comparatively stable compared to the past year. Enterprise Value Over EBITDA is likely to gain to 6.94 in 2024, whereas Selling General Administrative is likely to drop slightly above 3 B in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 5.1B | 5.3B | 4.9B | 3.7B | Total Revenue | 17.6B | 19.4B | 19.5B | 11.4B |
Fresenius Medical fundamental ratios Correlations
Click cells to compare fundamentals
Fresenius Medical Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Fresenius Medical fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 302.7M | 294.3M | 293.1M | 293.2M | 293.4M | 405.8M | |
Total Assets | 32.9B | 31.7B | 34.4B | 35.8B | 33.9B | 18.7B | |
Short Long Term Debt Total | 13.8B | 12.4B | 13.3B | 13.2B | 12.1B | 6.2B | |
Other Current Liab | 2.7B | 3.0B | 3.3B | 3.4B | 3.6B | 3.8B | |
Total Current Liabilities | 7.0B | 6.2B | 7.3B | 6.5B | 6.1B | 3.6B | |
Total Stockholder Equity | 13.2B | 12.3B | 14.0B | 15.4B | 13.6B | 7.8B | |
Property Plant And Equipment Net | 8.5B | 4.1B | 4.3B | 4.2B | 7.5B | 7.8B | |
Net Debt | 12.8B | 11.3B | 11.8B | 11.9B | 10.6B | 5.7B | |
Retained Earnings | 9.5B | 10.3B | 10.8B | 10.7B | 10.9B | 11.5B | |
Accounts Payable | 835.2M | 827.4M | 857.5M | 931.3M | 885.1M | 550.9M | |
Cash | 1.0B | 1.1B | 1.5B | 1.3B | 1.4B | 1.5B | |
Non Current Assets Total | 25.8B | 24.4B | 26.4B | 27.6B | 25.2B | 13.8B | |
Non Currrent Assets Other | 752.5M | 4.8B | 5.2B | 5.0B | 223.6M | 212.4M | |
Cash And Short Term Investments | 1.1B | 1.2B | 1.6B | 1.4B | 1.5B | 1.6B | |
Net Receivables | 4.0B | 3.6B | 3.9B | 4.0B | 4.1B | 2.6B | |
Common Stock Total Equity | 308.1M | 307.9M | 304.4M | 292.9M | 336.8M | 304.7M | |
Liabilities And Stockholders Equity | 32.9B | 31.7B | 34.4B | 35.8B | 33.9B | 18.7B | |
Non Current Liabilities Total | 12.7B | 13.2B | 13.1B | 13.8B | 13.0B | 7.2B | |
Inventory | 1.7B | 1.9B | 2.0B | 2.3B | 2.2B | 2.3B | |
Other Current Assets | 320.7M | 455.7M | 342.9M | 351.1M | 332.6M | 348.1M | |
Other Stockholder Equity | 4.5B | 4.0B | 4.2B | 4.8B | 3.4B | 3.2B | |
Total Liab | 19.7B | 19.4B | 20.4B | 20.3B | 19.1B | 10.8B | |
Property Plant And Equipment Gross | 8.5B | 8.2B | 4.3B | 4.2B | 17.9B | 17.0B | |
Total Current Assets | 7.2B | 7.3B | 8.0B | 8.2B | 8.7B | 4.9B | |
Accumulated Other Comprehensive Income | (1.0B) | (2.2B) | (1.3B) | (388.5M) | (975.2M) | (926.4M) | |
Short Term Debt | 3.3B | 1.7B | 2.6B | 2.0B | 1.6B | 1.1B | |
Intangible Assets | 1.4B | 1.4B | 1.5B | 1.5B | 1.4B | 1.7B | |
Common Stock | 304.4M | 292.9M | 293.0M | 293.4M | 337.4M | 258.6M | |
Current Deferred Revenue | 201.0M | 606.3M | 518.0M | 105.7M | 85.8M | 81.5M | |
Other Liab | 2.1B | 2.5B | 2.4B | 2.7B | 3.1B | 3.2B | |
Other Assets | 1.1B | 1.1B | 1.2B | 1.1B | 1.3B | 1.4B | |
Long Term Debt | 6.5B | 6.8B | 6.6B | 7.2B | 7.0B | 5.7B | |
Property Plant Equipment | 8.5B | 8.2B | 8.6B | 8.3B | 9.6B | 10.1B | |
Good Will | 14.0B | 13.0B | 14.4B | 15.8B | 14.7B | 13.9B | |
Short Term Investments | 133.3M | 161.7M | 136.4M | 170.0M | 136.3M | 140.2M | |
Net Tangible Assets | (3.5B) | (3.1B) | (3.1B) | (3.3B) | (3.8B) | (4.0B) | |
Long Term Investments | 696.9M | 761.1M | 786.9M | 773.7M | 1.3B | 853.1M | |
Short Long Term Debt | 2.6B | 1.1B | 1.9B | 1.4B | 944.6M | 1.7B |
Pair Trading with Fresenius Medical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Fresenius Medical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fresenius Medical will appreciate offsetting losses from the drop in the long position's value.Moving together with Fresenius Stock
0.69 | GH | Guardant Health Earnings Call Tomorrow | PairCorr |
Moving against Fresenius Stock
0.78 | CVS | CVS Health Corp Sell-off Trend | PairCorr |
0.75 | CAH | Cardinal Health Fiscal Year End 20th of August 2024 | PairCorr |
0.68 | SSY | SunLink Health Systems | PairCorr |
0.6 | HSCS | Heart Test Laboratories Upward Rally | PairCorr |
0.59 | NAOV | NanoVibronix | PairCorr |
The ability to find closely correlated positions to Fresenius Medical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Fresenius Medical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Fresenius Medical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Fresenius Medical Care to buy it.
The correlation of Fresenius Medical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Fresenius Medical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Fresenius Medical Care moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Fresenius Medical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fresenius Medical Care. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Complementary Tools for Fresenius Stock analysis
When running Fresenius Medical's price analysis, check to measure Fresenius Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius Medical is operating at the current time. Most of Fresenius Medical's value examination focuses on studying past and present price action to predict the probability of Fresenius Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius Medical's price. Additionally, you may evaluate how the addition of Fresenius Medical to your portfolios can decrease your overall portfolio volatility.
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Fresenius Medical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fresenius Medical. If investors know Fresenius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fresenius Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.17) | Dividend Share 1.19 | Earnings Share 0.89 | Revenue Per Share 33.185 | Quarterly Revenue Growth 0.004 |
The market value of Fresenius Medical Care is measured differently than its book value, which is the value of Fresenius that is recorded on the company's balance sheet. Investors also form their own opinion of Fresenius Medical's value that differs from its market value or its book value, called intrinsic value, which is Fresenius Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fresenius Medical's market value can be influenced by many factors that don't directly affect Fresenius Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fresenius Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Fresenius Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fresenius Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.